NASDAQ (usa) | 6715.56 | -12.11 | -0.18% | |
FTSE 100 (london) | 7487.96 | -5.12 | -0.07% | |
DAX (german) | 13465.51 | 235.94 | 1.78% | |
NIKKEI 225 (japan) | 22420.08 | 408.47 | 1.86% | |
Hang - Seng (hong kong) | 28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) | 3391.61 | 17.53 | 0.52% | |
KOSPI (korea) | 2556.47 | 33.04 | 1.31% | |
All Ordinaries (australia) | 6005.30 | 28.90 | 0.48% | |
BOVESPA (brazil) | 74092.76 | -215.73 | -0.29% |
Hanall Biopharma (KO: 009420)
009420 Technical Analysis
1
As on 29th Oct 2024 009420 STOCK Price closed @ 45700.00 and we RECOMMEND N/A for LONG-TERM with Stoploss of 0.00 & N/A for SHORT-TERM with Stoploss of 0.00 we also expect STOCK to react on Following IMPORTANT LEVELS. |
009420STOCK Price
Open | 45750.00 | Change | Price | % |
High | 46150.00 | 1 Day | N/A | N/A |
Low | 44550.00 | 1 Week | 0.00 | 0.00 |
Close | 45700.00 | 1 Month | 0.00 | 0.00 |
Volume | 661053 | 1 Year | 0.00 | 0.00 |
52 Week High 0.00 | 52 Week Low 0.00 |
KO Korea Most Active Stocks
007110 | 1644.00 | % |
007110 | 1644.00 | % |
096300 | 156.00 | -6.02% |
096300 | 156.00 | -6.02% |
005930 | 59600.00 | % |
009730 | 1697.00 | % |
037270 | 6490.00 | % |
037270 | 6490.00 | % |
034020 | 21850.00 | % |
034020 | 21850.00 | % |
KO Korea Top Losers Stocks
009420 Daily Charts |
009420 Intraday Charts |
Whats New @ Bazaartrend |
009420 Free Analysis |
|
009420 Important Levels Intraday
SUPPORT | 0.00 |
SUPPORT | 0.00 |
SUPPORT | 0.00 |
SUPPORT | 0.00 |
SUPPORT | 0.00 |
SUPPORT | 0.00 |
SUPPORT | 0.00 |
SUPPORT | 0.00 |
009420 Forecast October 2024
4th UP Forecast | 0 |
3rd UP Forecast | 0 |
2nd UP Forecast | 0 |
1st UP Forecast | 0 |
1st DOWN Forecast | 0 |
2nd DOWN Forecast | 0 |
3rd DOWN Forecast | 0 |
4th DOWN Forecast | 0 |
009420 Weekly Forecast
4th UP Forecast | 0.00 |
3rd UP Forecast | 0.00 |
2nd UP Forecast | 0.00 |
1st UP Forecast | 0.00 |
1st DOWN Forecast | 0.00 |
2nd DOWN Forecast | 0.00 |
3rd DOWN Forecast | 0.00 |
4th DOWN Forecast | 0.00 |
009420 Forecast2024
4th UP Forecast | 0 |
3rd UP Forecast | 0 |
2nd UP Forecast | 0 |
1st UP Forecast | 0 |
1st DOWN Forecast | 0 |
2nd DOWN Forecast | 0 |
3rd DOWN Forecast | 0 |
4th DOWN Forecast | 0 |
Hanall Biopharma ( KO Korea Symbol : 009420 )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
009420 Other Details
Segment | EQ | |
Market Capital | 1070211661824.00 | |
Sector | Healthcare | |
Industry | Drug Manufacturers-Specialty & Generic | |
Offical website | > echo $website ; ?> |
009420 Address
009420 Latest News
009420 Business Profile
Hanall Biopharma Co.,Ltd, a pharmaceutical company, researches, develops, and sells pharmaceutical products in South Korea and internationally. The company offers specialty drugs and over-the-counter products for the treatment of gastric and duodenal ulcers, gastritis, cerebrovascular and peripheral blood vessel disorder, hypertension, atherosclerotic symptom, acute coronary syndrome, atherothrombosis and thromboembolism, diabetes, osteoporosis, chronic kidney failure, hypothyroidism, vitamin D-resistant rickets, osteomalacia, erectile dysfunction, prostatic hyperplasia, candidiasis, various fungal infections, prostate cancer, formal, constipation, thin stools, bloating, bowel abnormal fermentation, and hemorrhoids. The company was founded in 1973 and is based in Seoul, South Korea. Address: Daewoong Building, Seoul, South Korea
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service